Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked...
Day: December 19, 2023
VPR Brands Acquires CARTDUB: Setting New Standards in Cannabis and Hemp Oil Recovery
FORT LAUDERDALE, FL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – VPR BRANDS LP (OTC: VPRB), a market leader...
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,...
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
RMAT designation intended to help expedite development of new regenerative medicines MALVERN, Pa., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc....
BrainsWay Highlights Expanded Deep TMS™ Access with Growing Western U.S. Network
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP) for the Submission of a Marketing Authorisation Application of Oral Blarcamesine for Alzheimer’s Disease
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock...
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel...
Kraig Biocraft Laboratories Announces Successful Production Test Utilizing a Two Strain Hybrid System
ANN ARBOR, Mich., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), the...
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to...
Atavistik Bio Raises Additional $40 Million to Advance Precision Allosteric Small Molecule Therapeutics
Proceeds will support lead precision oncology program into the clinic and advance earlier stage pipelineAtavistik Bio is discovering transformative precision...
Appointment of Chief Business Officer
19 December 2023 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Appointment of Chief Business Officer Appointment signals...
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder...
Treace to Present at 42nd Annual J.P. Morgan Healthcare Conference
Tuesday, January 9, 2024, at 3:45 pm Pacific TimePONTE VEDRA, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Treace Medical Concepts,...
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on...
SweetWater Brewing Announces 27th Anniversary Party Concert Lineup
SweetWater Brewing Company's Official 27th Anniversary Party Poster Join SweetWater for their 27th Anniversary happening on February 17th, 2024! EarthGang...
BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)
– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life...
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage...
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction
SUNNYVALE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment...
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis
NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...